Bio-Techne shareholders approve Merck KGaA acquisition; HSR waiting period expired

BIO-TECHNE Corp

Merger Agreement approved: 121,929,544 for, 1,208,817 against, 30,610 abstaining.
Non-binding advisory compensation vote failed: 25,912,275 for, 96,412,306 against.
HSR waiting period expired Sept 18, 2026; closing expected late 2026/early 2027.
CEO Kim Kelderman cites 'strong support' and near-term cash value for shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.